Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

Ferenci, Peter

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. [electronic resource] - Journal of viral hepatitis 06 2019 - 685-696 p. digital

Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't

1365-2893

10.1111/jvh.13080 doi


2-Naphthylamine
Adolescent
Adult
Aged
Aged, 80 and over
Anilides--therapeutic use
Antiviral Agents--therapeutic use
Carbamates--therapeutic use
Cyclopropanes
Drug Interactions
Drug Therapy, Combination
Female
Genotype
Hepacivirus--drug effects
Hepatitis C, Chronic--drug therapy
Humans
Internationality
Lactams, Macrocyclic
Macrocyclic Compounds--therapeutic use
Male
Middle Aged
Proline--analogs & derivatives
Prospective Studies
Ribavirin--therapeutic use
Ritonavir--therapeutic use
Sulfonamides--therapeutic use
Sustained Virologic Response
Uracil--analogs & derivatives
Valine
Young Adult